SCHEMBL70767

SCHEMBL70767

CON(C)C(=O)c1ncccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B1 P14061 1/20 0.39
TACR1 P25103 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MYC P01106 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
BLM P54132 1/20 0.37
AGER Q15109 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488783 0.83 TRPM8 (0.45) L3MBTL1KDM4EALDH1A1CYP3A4MAPT
SCHEMBL14818757 0.82 NOS3 (0.45) L3MBTL1SMN1; SMN2HSD17B1TACR1NPC1
SCHEMBL7072815 0.82 KDM4E (0.40) L3MBTL1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL2893762 0.82 L3MBTL1 (0.40) L3MBTL1SMN1; SMN2NPC1RAB9AMYC
SCHEMBL3488694 0.82 NFE2L2 (0.46) L3MBTL1SMN1; SMN2NPC1RAB9AHCRTR1
SCHEMBL569266 0.82 TRPM8 (0.40) L3MBTL1KDM4EALDH1A1CYP3A4MAPT
SCHEMBL31380314 0.80 PLCG1 (0.40) L3MBTL1KDM4EALDH1A1CYP3A4MAPT
SCHEMBL26874723 0.80 L3MBTL1 (0.38) L3MBTL1SMN1; SMN2MAPK1HCRTR1HCRTR2
SCHEMBL8988188 0.80 PARP1 (0.44) L3MBTL1SMN1; SMN2NPC1RAB9AHCRTR1
SCHEMBL29601266 0.78 HCRTR1 (0.49) SMN1; SMN2TACR1HCRTR1HCRTR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2024-01-18 US disclosed
WO-2023212693-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2023-11-02 WO disclosed
EP-2044052-B1 FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES BAYER IP GMBH (DE) 2013-06-05 EP disclosed
EP-2044052-B1 FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES BAYER IP GMBH (DE) 2013-06-05 EP disclosed
US-8129415-B2 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2012-03-06 US disclosed
US-8129415-B2 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2012-03-06 US disclosed
US-8129415-B2 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2012-03-06 US disclosed
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2009-07-30 US disclosed
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2009-07-30 US disclosed
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives BAYER CROPSCIENCE AG (DE) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192196-A1 Fungicide hydroximoyl-tetrazole derivatives HAAO, HAO1, CYP51A1 L3MBTL1 428/4885SMN1; SMN2 4339/4885MAPK1 2712/4885
US-20240018115-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 L3MBTL1 3117/4885SMN1; SMN2 1813/4885MAPK1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.